N6-methyladenosine modulation classes and immune microenvironment regulation in ischemic stroke

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• N6-methyladenosine (m6A) modifications are vital for immune cell differentiation and regulation.
• The role of m6A in ischemic stroke (IS) and its immune microenvironment is largely unexplored.

Purpose of the Study:

• To systematically assess m6A regulator expression patterns in IS.
• To investigate the association between m6A modifications and immune cell infiltration in IS.
• To identify potential diagnostic biomarkers and therapeutic targets for IS based on m6A modification.

Main Methods:

• Utilized GEO database (GSE16561 and GSE22255) for analyzing m6A regulator expression in IS.
• Employed logistic and LASSO regressions to screen for IS-related genes.
• Performed consistent clustering to classify IS samples and analyze immune cell infiltration differences.

Main Results:

• Identified significant upregulation of IGF2BP2, IGF2BP1, YTHDF2 and downregulation of ELAVL1, LRPPRC, METTL3, ALKBH5, CBLL1, METTL14 in IS.
• Developed a risk score model with an AUC of 0.942 based on seven key IS-related genes.
• Revealed significant differences in immune cell infiltration (memory B cells, CD8 T cells, monocytes, etc.) across m6A modification classes in IS.

Conclusions:

• m6A modification plays a critical role in the immune regulation of ischemic stroke.
• Distinct m6A modification patterns are associated with specific immune cell profiles and gene expression in IS.
• Identified 487 m6A-associated genes and 227 potential drugs, offering novel therapeutic avenues for IS.